Literature DB >> 21778574

BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Edgar S Diaz-Cruz1, Marina C Cabrera, Rebecca Nakles, Beth H Rutstein, Priscilla A Furth.   

Abstract

Genetically engineered mice along with allograft and xenograft models can be used to effectively model triple negative breast cancer both for studies of pathophysiology as well as preclinical prevention and therapeutic drug studies. In this review eight distinct genetically engineered mouse models of BRCA1 deficiency are discussed in relationship to the generation of triple negative mammary cancer. Allograft models derived from some of these genetically engineered mice are considered and xenograft models derived from breast cancers that developed from BRCA1 mutation are presented. Examples of the use of genetically engineered, allograft and xenografts models for preventive and therapeutic studies are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21778574      PMCID: PMC3500619          DOI: 10.3233/BD-2010-0308

Source DB:  PubMed          Journal:  Breast Dis        ISSN: 0888-6008


  72 in total

1.  Brca1 required for T cell lineage development but not TCR loci rearrangement.

Authors:  T W Mak; A Hakem; J P McPherson; A Shehabeldin; E Zablocki; E Migon; G S Duncan; D Bouchard; A Wakeham; A Cheung; J Karaskova; I Sarosi; J Squire; J Marth; R Hakem
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

2.  Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.

Authors:  A Loonstra; M Vooijs; H B Beverloo; B A Allak; E van Drunen; R Kanaar; A Berns; J Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

3.  Concurrent pregnancy retards mammary involution: effects on apoptosis and proliferation of the mammary epithelium after forced weaning of mice.

Authors:  Anthony V Capuco; Minglin Li; Ezhou Long; Shuxun Ren; Kathleen S Hruska; Kristel Schorr; Priscilla A Furth
Journal:  Biol Reprod       Date:  2002-05       Impact factor: 4.285

4.  Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.

Authors:  H Ruffner; C A Joazeiro; D Hemmati; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

5.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

Authors:  X Xu; W Qiao; S P Linke; L Cao; W M Li; P A Furth; C C Harris; C X Deng
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

6.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Authors:  Saijun Fan; Yong Xian Ma; Chenguang Wang; Ren-Qi Yuan; Qinghui Meng; Ji-An Wang; Michael Erdos; Itzhak D Goldberg; Paul Webb; Peter J Kushner; Richard G Pestell; Eliot M Rosen
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

8.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.

Authors:  S G Brodie; X Xu; W Qiao; W M Li; L Cao; C X Deng
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

Review 9.  BRCA1-associated tumorigenesis: what have we learned from knockout mice?

Authors:  S G Brodie; C X Deng
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

10.  Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice.

Authors:  Xiaoling Xu; Olga Aprelikova; Peter Moens; Chu-Xia Deng; Priscilla A Furth
Journal:  Development       Date:  2003-05       Impact factor: 6.868

View more
  14 in total

1.  Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.

Authors:  Yanying Huo; Hong Cai; Irina Teplova; Christian Bowman-Colin; Guanghua Chen; Sandy Price; Nicola Barnard; Shridar Ganesan; Vassiliki Karantza; Eileen White; Bing Xia
Journal:  Cancer Discov       Date:  2013-05-06       Impact factor: 39.397

2.  Manipulating the Mouse Genome Using Recombineering.

Authors:  Kajal Biswas; Shyam K Sharan
Journal:  Adv Genet Eng       Date:  2013-06-27

3.  Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.

Authors:  Sahar J Alothman; Weisheng Wang; David S Goerlitz; Md Islam; Xiaogang Zhong; Archana Kishore; Redha I Azhar; Bhaskar V Kallakury; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-10

Review 4.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

5.  Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Authors:  Sarah A Dabydeen; Keunsoo Kang; Edgar S Díaz-Cruz; Ahmad Alamri; Margaret L Axelrod; Kerrie B Bouker; Rawan Al-Kharboosh; Robert Clarke; Lothar Hennighausen; Priscilla A Furth
Journal:  Carcinogenesis       Date:  2014-11-23       Impact factor: 4.944

Review 6.  The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.

Authors:  Katie Lin; Stavroula Baritaki; Silvia Vivarelli; Luca Falzone; Aurora Scalisi; Massimo Libra; Benjamin Bonavida
Journal:  Antioxidants (Basel)       Date:  2022-06-17

7.  Primary cancer cell culture: mammary-optimized vs conditional reprogramming.

Authors:  Ahmad M Alamri; Keunsoo Kang; Svenja Groeneveld; Weisheng Wang; Xiaogang Zhong; Bhaskar Kallakury; Lothar Hennighausen; Xuefeng Liu; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2016-06-07       Impact factor: 5.678

8.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

9.  A DNA methylation-based definition of biologically distinct breast cancer subtypes.

Authors:  Olafur A Stefansson; Sebastian Moran; Antonio Gomez; Sergi Sayols; Carlos Arribas-Jorba; Juan Sandoval; Holmfridur Hilmarsdottir; Elinborg Olafsdottir; Laufey Tryggvadottir; Jon G Jonasson; Jorunn Eyfjord; Manel Esteller
Journal:  Mol Oncol       Date:  2014-11-05       Impact factor: 6.603

10.  The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis.

Authors:  Uri Ben-David; Gavin Ha; Prasidda Khadka; Xin Jin; Bang Wong; Lude Franke; Todd R Golub
Journal:  Nat Commun       Date:  2016-07-04       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.